These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36199784)

  • 1. Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis.
    Lee YP; Lee MS; Yoon SE; Cho J; Bang YH; Shim JH; Kim WS; Kim SJ
    J Oncol; 2022; 2022():2263217. PubMed ID: 36199784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
    Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
    Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group.
    Jurinovic V; Metzner B; Pfreundschuh M; Schmitz N; Wandt H; Keller U; Dreger P; Dreyling M; Hiddemann W; Unterhalt M; Hoster E; Weigert O
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1172-1179. PubMed ID: 29605716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
    Muntañola A; Mozas P; Mercadal S; Huguet M; Bobillo S; Bastos-Oreiro M; Jiménez-Ubieto A; Rovira J; Rivero A; Tolosa C; Luizaga L; de Villambrosia SG; Novelli S; Caballero D; Salar A; Alonso-Álvarez S; Magnano L; Gutiérrez NC; Sancho JM; López-Guillermo A;
    Br J Haematol; 2023 Feb; 200(3):306-314. PubMed ID: 36261137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
    Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
    Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Follicular lymphoma: first - line selection criteria of treatment].
    Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
    Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months.
    Yoon SE; Cho J; Kim WS; Kim SJ
    J Cancer; 2021; 12(9):2488-2497. PubMed ID: 33854610
    [No Abstract]   [Full Text] [Related]  

  • 9. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Leuk Lymphoma; 2006 Aug; 47(8):1545-52. PubMed ID: 16966265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
    Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
    Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.
    Epperla N; Welkie RL; Torka P; Shouse G; Karmali R; Shea L; Anampa-Guzmán A; Oh TS; Reaves H; Tavakkoli M; Lindsey K; Greenwell IB; Hansinger E; Thomas C; Chowdhury SM; Annunzio K; Christian B; Barta SK; Geethakumari PR; Bartlett NL; Herrera AF; Grover NS; Olszewski AJ
    J Hematol Oncol; 2023 May; 16(1):49. PubMed ID: 37158890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis.
    Wullenkord R; Berning P; Niemann AL; Wethmar K; Bergmann S; Lutz M; Schliemann C; Mesters R; Keßler T; Schmitz N; Berdel WE; Lenz G; Stelljes M
    Ann Hematol; 2021 Nov; 100(11):2733-2744. PubMed ID: 34477953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.
    Alig S; Jurinovic V; Shahrokh Esfahani M; Haebe S; Passerini V; Hellmuth JC; Gaitzsch E; Keay W; Tahiri N; Zoellner A; Rosenwald A; Klapper W; Stein H; Feller A; Ott G; Staiger AM; Horn H; Hansmann ML; Pott C; Unterhalt M; Schmidt C; Dreyling M; Alizadeh AA; Hiddemann W; Hoster E; Weigert O
    Blood Adv; 2020 Sep; 4(18):4451-4462. PubMed ID: 32941649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
    Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
    Casulo C; Dixon JG; Le-Rademacher J; Hoster E; Hochster HS; Hiddemann W; Marcus R; Kimby E; Herold M; Sebban C; Gyan E; Foon K; Nielsen T; Vitolo U; Salles GA; Shi Q; Flowers CR
    Blood; 2022 Mar; 139(11):1684-1693. PubMed ID: 34614146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
    Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors JM; Gascoyne RD; Hiddemann W; Unterhalt M; Weinstock DM; Weigert O
    Blood; 2016 Aug; 128(8):1112-20. PubMed ID: 27418643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group.
    Muntañola A; Baumann T; Caballero AC; Sánchez-González B; Mercadal S; Escoda L; Soler A; Iserte L; Canet M; Villalobos MT; Magnano L; Sorigué M; García O; Salar A; López-Guillermo A; Sancho JM
    Ann Hematol; 2020 Jul; 99(7):1627-1634. PubMed ID: 32451707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
    Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China.
    Liu J; Hu Y; Zhao L; Nuersulitan R; Liu Y; Yu H; Ye Y; Wang D; Tang Y; Feng F; Liu W; Zhu J; Ping L; Song Y
    Front Oncol; 2023; 13():1264723. PubMed ID: 37941553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.